SIRT3, downregulated in prostate cancer, acts as a tumor suppressor, modulating protein kinase B and Wnt/β-catenin pathways, inhibiting migration and proliferation (Li et al., 2018). The gene discussed is SIRT3; the disease is neoplasm.